IL6 and cancer: Dual treatment of MSL TNBC cell lines with docetaxel and an IL-6 neutralizing antibody led to a significant reduction in phosphorylation of STAT3, a potent transcription factor for cancer proliferation (Fig. 4a and Supplementary Fig. 6A).